Last reviewed · How we verify

aspirin (ASA) — Competitive Intelligence Brief

aspirin (ASA) (aspirin (ASA)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent. Area: Cardiovascular; Pain management; Immunology.

marketed Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) Cardiovascular; Pain management; Immunology Small molecule Live · refreshed every 30 min

Target snapshot

aspirin (ASA) (aspirin (ASA)) — Janssen Scientific Affairs, LLC. Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
aspirin (ASA) TARGET aspirin (ASA) Janssen Scientific Affairs, LLC marketed Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Rectal Indomethacin Rectal Indomethacin Moti Lal Nehru Medical College marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Diclofenac Sodium gel, 1% Diclofenac Sodium gel, 1% Glenmark Pharmaceuticals Ltd. India marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Ibuprofen 2% Ibuprofen 2% Berlin-Chemie AG Menarini Group marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-1, COX-2
Aspirin 81 enteric coated tablet daily Aspirin 81 enteric coated tablet daily University of Florida marketed Antiplatelet agent / Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1)
Indometacin Cataplasms Indometacin Cataplasms Guang'anmen Hospital of China Academy of Chinese Medical Sciences marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)
Ketorolac, intramuscular Ketorolac, intramuscular The University of Texas Medical Branch, Galveston marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent class)

  1. Assistance Publique - Hôpitaux de Paris · 3 drugs in this class
  2. Basque Health Service · 2 drugs in this class
  3. PLx Pharma · 2 drugs in this class
  4. Biogen · 1 drug in this class
  5. Eli Lilly and Company · 1 drug in this class
  6. Harbin Medical University · 1 drug in this class
  7. Janssen Scientific Affairs, LLC · 1 drug in this class
  8. Azienda Ospedaliera San Giovanni Battista · 1 drug in this class
  9. Royal College of Surgeons, Ireland · 1 drug in this class
  10. Shiraz University of Medical Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). aspirin (ASA) — Competitive Intelligence Brief. https://druglandscape.com/ci/aspirin-asa. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: